Bibliography
- Triggle DJ. Drug discovery and delivery in the 21st Century. Med Princ Pract 2007;16:1-14
- Haworth IS. Computational drug delivery. Adv Drug Deliv Rev 2006;58(12-13):1271-3
- Lin J, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49(4):403-49
- Rao VS, Srinivas K. Modern drug discovery process: an in silico approach. J Bioinform Seq Anal 2011;2(5):89-94
- Williams M. Strategies for drug discovery. NIDA Res Monogr 1993;132:1-22
- Stegemann S, Leveiller F, Franchi D, et al. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci 2007;31(5):249-61
- McAllister M. Selecting formulations for drug discovery and early drug development – current challenges and emerging approaches for predicting bioperformance. Pharmaceutical Outsourcing. 2013. Available from: http://www.pharmoutsourcing.com/Featured-Articles/129473 [Last accessed December 11, 2013]
- Chaubal MV. Application of formulation technologies in lead candidate selection and optimization. Drug Discov Today 2004;9(14):603-9
- Veber DF, Johnson SR, Cheng H-Y, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45(12):2615-23
- Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23(1-3):3-25
- Dressman JB, Reppas C. In vitro– in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000;11(Suppl 2):S73-80
- Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12(3):413-20
- Tihanyi K, Vastag M. Solubility, delivery and ADME problems of drugs and drug-candidates. Bentham-eBook 2011. Available from: http://www.benthamscience.com/ebooks/contents.php?JCode=9781608051205 [Last accessed 13 Oct 2013]
- Chandra N. Computational systems approach for drug target discovery. Expert Opin Drug Discov 2009;4(12):1221-36
- Vanjari SS, Chimandare N, Gandhi SV. A review on in silico approach in pharmacology. Adv Res Pharm Biol 2012;2(2):129-41
- Karelson M. Molecular descriptors in QSAR/QSPR. Wiley-VCH, New York; 2000
- Kar S, Roy K. How far can virtual screening take us in drug discovery? Expert Opin Drug Discov 2013;8(3):245-61
- Canduri F, de Azevedo WF. Protein crystallography in drug discovery. Curr Drug Targets 2008;9(12):1048-53
- de Azevedo WF Jr. Molecular dynamics simulations of protein targets identified in Mycobacterium tuberculosis. Curr Med Chem 2011;18(9):1353-66
- Azevedo LS, Moares FP, Xavier MM, et al. Recent progress of molecular docking simulations applied to development of drugs. Curr Bioinform 2012;7(4):352-65
- Heberlé G, de Azevedo WF Jr. Bio-inspired algorithms applied to molecular docking simulations. Curr Med Chem 2011;18(9):1339-52
- de Azevedo WF Jr, Dias R. Computational methods for calculation of ligand-binding affinity. Curr Drug Targets 2008;9(12):1031-9
- Bello M, Martinez-Archundia M, Correa-Basurto J. Automated docking for novel drug discovery. Expert Opin Drug Discov 2013;8(7):821-34
- Satyajit D, Sovan S, Kapil S. Computer-aided drug design – a new approach in drug design and discovery. Int J Pharm Sci Rev Res 2010;4(3):156-67
- Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 2007;152(1):9-20
- Zheng M, Liu X, Xu Y, et al. Computational methods for drug design and discovery: focus on China. Trends Pharmacol Sci 2013;34(10):549-59
- Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303:1813-18
- Morphy R. Rankovic: designed multiple ligands: an emerging drug discovery paradigm. J Med Chem 2005;48:6523-43
- Knowles J, Gromo G. Target selection in drug discovery. Nat Rev Drug Discov 2003;2:63-9
- Li H, Zheng M, Luo X, Zhu W, Jiang H. Drug discovery and development: computational approaches. Wiley encyclopedia of chemical biology. John Wiley & Sons, Inc., Hoboken; 2008. p. 1-9
- Anderson AC. The process of structure-based drug design. Chem Biol 2003;10:787-97
- Otto S, Furlan RLE, Sanders JKM. Dynamic combinatorial chemistry. Drug Discov Today 2002;7:117-25
- Baldi A. Computational approaches for drug design and discovery: an overview. Syst Rev Pharm 2010;1:99-105
- Kumar N, Hendricks BS, Janes KA, et al. Applying computational modeling to drug discovery and development. Drug Discovery Today 2006;11(17/18):806-11
- Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 2004;5:262-75
- Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol 2007;152(1):38-52
- Buchwald P, Bodor N. Computer-aided drug design: the role of quantitative structure–property, structure–activity and structure metabolism relationships (QSPR, QSAR, and QSMR). Drug Future 2002;27(6):577-88
- Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002;42:620-43
- Karalis V, Macheras P, Van Peer A, et al. Bioavailability and bioequivalence: focus on physiological factors and variability. Pharm Res 2008;25:1956-62
- Song NN, Zhang SY, Liu CX. Overview of factors affecting oral drug absorption. Asian J Drug Metab Pharmacokinet 2004;4(3):167-76
- Borchardt RT, Kerns EH, Hageman MJ, et al., editors. Optimizing the “drug-like” properties of leads in drug discovery. AAPS Press, Springer, New York; 2007. p. 522
- Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44(1):235-49
- Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development Settings. Adv Drug Deliv Rev 2001;46:3-26
- Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615-23
- Bergström CAS, Norinder U, Luthman K, et al. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm Res 2002;19(2):182-8
- Bergström CAS, Wassvik CM, Norinder U, et al. Global and local computational models for prediction of aqueous solubility of drug-like molecules. J Chem Inf Comput Sci 2004;44:1477-88
- Boobis A, Gundert-Remy U, Kremers P, et al. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur J Pharm Sci 2002;17:183-93
- Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7(2):165-82
- Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm 2007;341:1-19
- Baillie TA. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 2008;21:129-37
- Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Food and Drug Administration; Rockville, MD: 2000. Available from: http://www.fda.gov/cder/guidance/index.htm
- Ku MS. Use of the biopharmaceutical classification system in early drug development. AAPS J 2008;10(1):208-12
- Dickinson PA, Lee WW, Stott PW, et al. Clinical relevance of dissolution testing in quality by design. AAPS J 2008;10(2):380-90
- Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23
- Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J 2011;13(4):519-47
- Benet LZ. The role of BCS (Biopharmaceutics Classification System) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci 2013;102(1):34-42
- Emami J. In vitro - in vivo correlation: from theory to applications. J Pharm Pharm Sci 2006;9(2):31-51
- Cardot JM, Beyssac E, Alric M. In vitro– in vivo correlation: importance of dissolution in IVIVC. Dissol Technol 2007;14:15-19
- US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry, extended release oral dosage forms: development, evaluation and application of an in vitro/in vivo correlation. Rockville, USA; 1997. Available from: http://www.fda.gov/cder/guidance/index.htm
- Sakore S, Chakraborty B. In vitro– in vivo correlation (IVIVC): a strategic tool in drug development. J Bioequiv Availab 2011;S3:1-12
- Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Tech 1996;20(6):64-74
- FDA. Guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. 2000. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf
- EMA. Guideline on the investigation of bioequivalence. 2010. Available from: http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2010/01/WC500070039.pdf
- WHO. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Annex. 7, WHO Technical Report Series 937. 2006. Available from: http://whqlibdoc.who.int/trs/WHOTRS937eng.pdf
- Kawabata Y, Wada K, Nakatani M, et al. Formulation design for poorly water-soluble drugs based on Biopharmaceutics Classification System: basic approaches and practical applications. Int J Pharm 2011;420:1-10
- Sun L, Liu X, Xiang R, et al. Structure-based prediction of human intestinal membrane permeability for rapid in silico BCS classification. Biopharm Drug Dispos 2013;34(6):321-35
- Tsume Y, Langguth P, Garcia-Arieta A, et al. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharm Drug Dispos 2012;33(7):366-77
- Sjogren E, Westergren J, Grant I, et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci 2013;49:679-98
- Heimbach T, Xia B, Lin T, et al. Case studies for practical food effect assessments across bcs/bddcs class compounds using in silico, in vitro, and preclinical in vivo data. AAPS J 2013;15:143-58
- CFR – Code of federal regulations title 21 – part 320 bioavailability and bioequivalence requirement. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Silver Spring, USA; 2013. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=320
- European Medicines Agency. Committee For Medicinal Products For Human Use (CHMP). Guideline on the investigation of bioequivalence, London; 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
- Leucuta SE. Systemic and biophase bioavailability and pharmacokinetics of nanoparticulate drug delivery systems. Curr Drug Deliv 2013;10:208-40
- Leucuta SE. Drug delivery systems with modified release for systemic and biophase bioavailability. Curr Clin Pharmacol 2012;7(4):282-317
- Leucuta SE. Subcellular drug targeting, pharmacokinetics and bioavailability. J Drug Target 2013; In press
- Leucuta SE. Nanotechnology for delivery of drugs and biomedical applications. Curr Clin Pharmacol 2010;5:257-80
- Martin A, Bustamante P, Chun AHC. Physical pharmacy. 4th edition. Lea&Febiger; Philadelphia, London; 1993
- Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. 3rd edition. Lea&Febiger; Philadelphia; 1986
- Yalkowsky SH, Krzyzaniak JF, Ward GH. Formulation-related problems associated with intravenous drug delivery. J Pharm Sci 1998;87:787-96
- Saleh AM, Daabis NA. Study of the interaction of menadione with hydrotropic salts. Pharmazie 1974;29:525-7
- Duchêne D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. J Control Release 1999;62(1-2):263-8
- Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897;19:930-4
- Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 2007;4:403-16
- Beg S, Swain S, Rizwan M, et al. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. Curr Drug Deliv 2011;8(6):601-702
- Leucuta SE, Achim M, Dinte E, et al. Technologie pharmaceutique, Editura Medicala Universitara “Iuliu Hatieganu” Cluj-Napoca; 2006. p. 539. Available from: http://www.umfcluj.ro/index.php/ro/educatie-ro/reurseedu-ro/editura-ro
- Aulton ME. Pharmaceutics: the science of dosage form design. 2nd edition. Churchill-Livingstone, London; 2002
- Schultheis N, Newman A. Pharmaceutical cocrystals and their physico-chemical properties. Cryst Growth Des 2009;9:2950-67
- Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281-302
- Yasuji T, Takeuchi H, Kawashima Y. Particle design of poorly water soluble drug substances using supercritical fluid technologies. Adv Drug Deliv Rev 2008;60:388-98
- Repka MA, Majumdar S, Kumar Battu S, et al. Applications of hot melt extrusion for drug delivery. Expert Opin Drug Deliv 2008;5:1357-76
- Zheng W, Jain A, Papoutsakis D, et al. Selection of oral bioavailability enhancing formulations during drug discovery. Drug Dev Ind Pharm 2012;38(2):235-47
- Ritika SL, Aggarwal H, Aggarwal G. Formulation tactics for the delivery of poorly soluble drugs. Int J Pharm Tech Res 2012;4(3):914-23
- Edward LL, Steven CS. In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement. Adv Drug Deliv Rev 1997;23:163-83
- Carsten B, Adrian F, Urte K, et al. Comparison of permeation enhancing strategies for an oral factor inhibitor using the Caco-2 cell monolayer model. Eur J Pharm Biopharm 2006;64:229-37
- ICH harmonized tripartite guideline: pharmaceutical development Q8(R2), current step 4 version. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf
- Department of Health and Human Services, US Food and Drug Administration Pharmaceutical cGMPs for the 21st century – a risk-based approach. Rockville, USA; 2004. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/UCM176374.pdf
- Tomuta I, Iovanov R, Vonica AL, et al. High-Throughput NIR-Chemometric method for meloxicam assay from powder blends for tableting. Sci Pharm 2011;79(4):885-98
- Tomuta I, Bodoki E, Leucuta SE. Quantification of meloxicam and excipients on intact tablets by near infrared spectrometry and chemometry. Farmacia 2010;58(5):559-71